Myrtle Potter has served as Chairman of our board of directors since August 2018. Ms. Potter has served as Chief Executive Officer of Sumitovant Biophama, Inc. since December 2019. Sumitovant Biopharma is a global biopharmaceutical company that is the parent to five biopharma companies. Formerly she served as Vant Operating Chair of Roivant Sciences from July 2018 to December 2019, where she oversaw a portfolio of thirteen biopharmaceutical companies and guided the initial public offerings of two. She founded Myrtle Potter & Company, LLC, a life sciences advisory firm, in September 2005 and served as the CEO until June 2018. She and her 100+ team of experts led major strategic efforts, including clinical development and product launch readiness efforts for numerous biopharmaceutical companies. Potter previously served as Chief Operating Officer, and later, President of Genentech, Inc. during a pivotal period of the company’s history. Under her leadership, Genentech achieved record sales and earnings growth for nineteen of twenty consecutive quarters. During this time, she was Co-Chair of the company’s Product Portfolio Committee that made all investment decisions for Genentech’s clinical development portfolio. Prior to Genentech, Potter was President of Bristol-Myers Squibb’s 3,500-person U.S. Cardiovascular and Metabolic business. Earlier she served at Merck where she founded and launched Astra/Merck, Inc. that today operates as AstraZeneca. Ms. Potter serves as Chairman of the Board of Myovant Sciences and serves on the boards of Liberty Mutual Holding Company and Axsome Therapeutics. She previously served on the boards of Amazon, Medco Health Solutions, Inc., Express Scripts Holding Co., Everyday Health, Inc, as well as numerous other public and private companies. Ms. Potter is a graduate of the University of Chicago where she is a Trustee.

Yuichiro Haruyama has served as a member of our board of directors since April 2021. Mr. Haruyama serves as Chief Financial Officer and a member of the board of Sumitovant Biopharma. Mr. Haruyama was instrumental in creating the broad strategic partnership between Sumitomo Dainippon Pharma and Roivant Sciences in 2019, including forming Sumitovant Biopharma. He started his career at Sumitomo Chemical, a leading Japanese chemical company, in 1993 and, since then, he has played a leading role in global pharmaceutical/chemical operations, corporate strategy, business development and finance. At Sumitomo Chemical, he was responsible for designing and implementing strategy for OLED (organic light-emitting diode) business, including a number of partnerships with global electronics companies, as well as oversaw its global operations. As Sumitomo Dainippon Pharma, he served as a key member in developing the corporate mid-term business plan in 2019, setting up and managing global business operations, such as the U.S., UK and Chinese affiliate companies, and leading a number of M&A efforts. Mr. Haruyama earned a Bachelor of Science degree in Business and Commerce at Keio University in Tokyo and an MBA in finance from Indiana University in Bloomington, Indiana.

James M. Hindman has served as a member of our board of directors since May 2020. Mr. Hindman has over 30 years of global and strategic financial experience in the biopharmaceutical and medical device industries, including the urology, ophthalmology, neurology, dermatology, and medical aesthetics therapeutic areas. He enjoyed a long and successful career at Allergan, most recently serving as Chief Financial Officer and Executive Vice President of Finance and Business Development until Allergan’s $70.5B sale to Actavis in 2015. Under Mr. Hindman’s leadership, Allergan achieved its most robust financial performance in the company’s then 60+-year history. He was instrumental in facilitating the largest restructuring of Allergan, creating $20B in shareholder value that ultimately led to the Actavis acquisition and the creation of a top 10 global pharmaceutical firm. In addition to serving as Chief Financial Officer, Mr. Hindman held various senior leadership positions during his tenure at Allergan, including Senior Vice President, Finance, and Controller. He also led several strategic functions at the company, including treasury, investor relations, risk, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning. Additionally, he served as President of the Allergan Foundation from 2009 to 2015. Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves on the boards of Millendo Therapeutics, Accuray, Inc, and Aatru Medical, and is a member of the Loyola Marymount University Board of Regents.

Sef P. Kurstjens, M.D., Ph.D. has served as a member of our board of directors since July 2018. Dr Kurstjens most recently served as Chief Medical Officer at Astellas from April 2013 to April 2018. At Astellas, Dr. Kurstjens was responsible for development, regulatory affairs, medical affairs, pharmacovigilance and quality assurance and was a member of the Corporate Executive Committee. From 2010 to 2013, Dr. Kurstjens was the President and Chief Executive Officer at Agensys, Inc., an early stage oncology Astellas affiliate. Previously, from 2007 to 2010, Dr. Kurstjens served as the Senior Vice President, Chief Medical Officer and Head, Global Drug Development at Allergan. Dr. Kurstjens entered the pharmaceutical industry with Sandoz Pharmaceuticals (now a Novartis International AG company) in Basel, Switzerland in 1991, and from 1993 to 2005 held positions of increasing responsibility with Pfizer Inc. in both Europe and the United States, including VP Worldwide Therapeutic Area Head of Gastrointestinal and Genitourinary. Dr. Kurstjens received his qualifications in medicine and physiology from University of the Witwatersrand in Johannesburg, South Africa.

Pierre Legault has served as a member of our board of directors since July 2018 and as our Lead Independent Director since December 2019. Mr. Legault also currently serves as board director and chairman of Poxel SA, Bicycles Therapeutics Inc., Amolyt Pharmaceuticals Inc, and Artios Pharma Limited. Mr. Legault also serves as a board director of Syndax Pharmaceuticals Inc. Previously, Mr. Legault served as a member of the boards of directors at Forest Laboratories, Inc., Clementia Pharmaceuticals Inc., Tobira Therapeutics, Inc., NPS Pharmaceuticals, Inc., Regado Biosciences, Inc., ARMO Biosciences, Iroko Pharmaceuticals LLC, Cyclacel Pharmaceuticals Inc., Eckerd Pharmacy and NephroGenex, Inc., where he also served as the Chairman and Chief Executive Officer. From 2010 to 2012, Mr. Legault served as the Chief Executive Officer of Prosidion Ltd., a subsidiary of Astellas, and he served as the Chief Financial Officer and Treasurer of OSI Pharmaceuticals, Inc from 2009 to 2010. Mr. Legault also previously served as the President of Eckerd Pharmacy and Senior Executive Vice President and Chief Administrative Officer of the Rite Aid Corporation. Between 1989 and 2005, Mr. Legault held various global roles such as President, Chief Executive Officer and Chief Financial Officer at legacy companies of the Sanofi-Aventis group. Mr. Legault earned a B.B.A. in Business & International Finance from HEC Montreal, an M.B.A. in Marketing from McGill University and holds C.A. and C.P.A. diplomas. He also studied at Harvard Business School in their Graduate Executive MBA program.

Shigeyuki Nishinaka, Ph.D. has served as a member of our board of directors since December 2019. Dr. Nishinaka joined Sumitomo Dainippon Pharma in 2009 and currently serves as Executive Officer, Global Business Development, International Business Management. Sumitomo Dainippon Pharma is a leading global Japanese pharmaceutical company with leading prescription drugs in the United States and other markets and has more than 6,000 employees worldwide. Dr. Nishinaka has more than 25 years of experience in drug development, drug commercialization, and mergers and acquisitions and has served in several leadership roles at Sumitomo Dainippon Pharma and Daiichi Sankyo. Dr. Nishinaka also serves on the board of directors of Meltin MMI, a medical technology company focused on the research and development and commercialization of medical devices and avatar robots. Dr. Nishinaka earned his Ph.D. from Hiroshima University, where he also completed a master’s course in Biosphere Science.

Jim Robinson was appointed President and Chief Executive Officer of Urovant on March 23, 2020, having served as a member of our board of directors since March 2019. Mr. Robinson is a proven leader in the biopharmaceutical and healthcare industries having successfully led multiple global businesses, operations and commercial ventures in multiple corporations over the past 28 years. Most recently, Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences where he oversaw Paragon’s operations. Previously, Mr. Robinson served as the President and Chief Operating Officer of Alkermes, where he was responsible for global commercial, new product planning, corporate planning, manufacturing, quality, human resources and business development functions. Prior to Alkermes, Mr. Robinson spent over twelve years at Astellas U.S. – most recently as President, Americas Operations where his responsibilities included all aspects of operations for North and South America. Prior to that, he was President of Astellas Pharma US, where he was responsible for leading the U.S. commercial organization. Prior to Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals where his last role was Vice President, Hepatitis Sales and Managed Care. Mr. Robinson serves on the Board of Directors for Neos Therapeutics and the Chicago Botanic Garden and is a founding member of MATTER. Previously, Mr. Robinson served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and served as Chairman of PhRMA’s State Committee. Mr. Robinson received a Bachelor of Science degree from DePaul University.